#celltrion

Collection of celltrion news, found 8 news.

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

  • 3rd January 2022

Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the ...

Celltrion’s monoclonal antibody treatment regdanvimab, approved by the European Commission for the treatment of COVID-19

Celltrion’s monoclonal antibody treatment regdanvimab, approved by the European Commission for the treatment of COVID-19

  • 15th November 2021

Celltrion Group announced today that the European Commission (EC) has approved Regkirona (regdanvimab, CT-P59), one of ...

Celltrion receives CHMP positive opinion for regdanvimab (CT-P59) as one of the first monoclonal antibodies recommended as a treatment for COVID-19 by the CHMP

Celltrion receives CHMP positive opinion for regdanvimab (CT-P59) as one of the first monoclonal antibodies recommended as a treatment for COVID-19 by the CHMP

  • 12th November 2021

Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for ...

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

  • 20th September 2021

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a ...

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

  • 15th June 2021

infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)1 Incheon, South Korea--(Antara/Business ...

Pandjaitan visits South Korea to boost pharmaceutical investment

Pandjaitan visits South Korea to boost pharmaceutical investment

  • 28th May 2021

Coordinating Maritime Affairs and Investment Minister Luhut Binsar Pandjaitan embarked on a work visit to South Korea ...

Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

  • 20th May 2021

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed ...

MPM Holdings Inc. enters into agreement to be acquired by investor group consisting of SJL Partners, KCC Corporation and Wonik QnC Corporation

MPM Holdings Inc. enters into agreement to be acquired by investor group consisting of SJL Partners, KCC Corporation and Wonik QnC Corporation

  • 13th September 2018

- MPM Holdings Inc. ("Momentive" or the "Company") (OTCQX:MPMQ), a global silicones and advanced materials company, and ...